Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865339 · ClinicalTrials.gov registry record · Phase 2
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
A Phase 2 study of NSCLC and Locally Advanced, sponsored by Nitin Ohri.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06865339 is a Phase 2 study of NSCLC and Locally Advanced that is actively recruiting participants, run by Nitin Ohri. The registered enrollment target is 76 participants, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06865339, a Phase 2 study of NSCLC and Locally Advanced, is actively recruiting participants, sponsored by Nitin Ohri.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
Conditions Studied
Interventions
- DRUG Cemiplimab
- RADIATION Radiotherapy
- DRUG Fianlimab
- DRUG Platinum Doublet Chemotherapy (PDC)
Study Locations (1)
New York
- Montefiore Einstein Comprehensive Cancer Center (MECCC) - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06865339
The ClinicalTrials.gov registry entry for NCT06865339 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (66% lower). The listed sponsor is Nitin Ohri, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NSCLC appearing as the primary indexed condition, and to 4 interventions - of which Cemiplimab is the first listed.
NCT06865339 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06865339 about?
NCT06865339 is a clinical study titled "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer". Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
What is the current status of trial NCT06865339?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-08-07. Estimated completion is 2027-08.
What conditions does trial NCT06865339 study?
This clinical trial studies the following conditions: NSCLC, Locally Advanced.
What interventions are being tested in trial NCT06865339?
The interventions under investigation include: Cemiplimab (DRUG), Radiotherapy (RADIATION), Fianlimab (DRUG), Platinum Doublet Chemotherapy (PDC) (DRUG).
Who is sponsoring clinical trial NCT06865339?
This trial is sponsored by Nitin Ohri, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865339 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.